Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 5,847 shares at $1.33 ($8K) on 2024-02-15, disclosed to the SEC on 2024-02-20.
Open-market sale of $8k KPTI by EVP, Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.33 | 5,748 | $8K | 98.2% |
| 2 | $1.40 | 99 | $139 | 1.8% |
| Total | $1.33 avg | 5,847 | $8K | 100% |
| Filing → |
| KPTI | SELL | 2026-03-03 | $48K | — | Filing → |
| KPTI | SELL | 2026-02-19 | $3K | — | Filing → |
| KPTI | SELL | 2025-09-16 | $3K | — | Filing → |